Difludiazepam
Chemical compound
- CA: Schedule IV
- DE: NpSG (Industrial and scientific use only)
- UK: Under Psychoactive Substances Act
- 7-chloro-5-(2,6-difluorophenyl)-1-methyl-1H-benzo[e] [1,4]diazepin-2(3H)-one
- 39080-67-6 Y
- 44366236
- 23222150
- 7N3B9XEC7B
- ChEMBL346673
- Interactive image
- Fc3cccc(F)c3C2=NCC(=O)N(C)c1ccc(Cl)cc12
InChI
- InChI=1S/C16H11ClF2N2O/c1-21-13-6-5-9(17)7-10(13)16(20-8-14(21)22)15-11(18)3-2-4-12(15)19/h2-7H,8H2,1H3
- Key:DUNFPASORLTEGN-UHFFFAOYSA-N
Difludiazepam[1] (Ro07-4065) is a benzodiazepine derivative which is the 2',6'-difluoro derivative of fludiazepam. It was invented in the 1970s but was never marketed, and has been used as a research tool to help determine the shape and function of the GABAA receptors, at which it has an IC50 of 4.1nM.[2][3][4] Difludiazepam has subsequently been sold as a designer drug, and was first notified to the EMCDDA by Swedish authorities in 2017.[5][6]
See also
References
- ^ Maskell PD, Wilson NE. Designer Benzodiazepines: New Challenges and Treatment Options, in Corazza O, Roman-Urrestarazu. Handbook of Novel Psychoactive Substances: What Clinicians Should Know about NPS. Taylor & Francis, 2019. ISBN 978-1-138-06830-8
- ^ Winkler DA, Burden FR, Watkins AJ (January 1998). "Atomistic Topological Indices Applied to Benzodiazepines using Various Regression Methods". Quantitative Structure-Activity Relationships. 17 (1): 14–19. doi:10.1002/(SICI)1521-3838(199801)17:01<14::AID-QSAR14>3.0.CO;2-U.
- ^ So SS, Karplus M (December 1996). "Genetic neural networks for quantitative structure-activity relationships: improvements and application of benzodiazepine affinity for benzodiazepine/GABAA receptors". Journal of Medicinal Chemistry. 39 (26): 5246–5256. doi:10.1021/jm960536o. PMID 8978853.
- ^ Maddalena DJ, Johnston GA (February 1995). "Prediction of receptor properties and binding affinity of ligands to benzodiazepine/GABAA receptors using artificial neural networks". Journal of Medicinal Chemistry. 38 (4): 715–724. doi:10.1021/jm00004a017. PMID 7861419.
- ^ Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA (PDF). Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and Europol. 2018. ISBN 978-92-9497-348-1.
- ^ Manchester KR, Waters L, Haider S, Maskell PD (July 2022). "The blood-to-plasma ratio and predicted GABAA-binding affinity of designer benzodiazepines". Forensic Toxicology. 40 (2): 349–356. doi:10.1007/s11419-022-00616-y. PMC 9715504. PMID 36454409.
- v
- t
- e
- 2-Oxoquazepam
- 3-Hydroxyphenazepam
- Bromazepam
- BMS-906024*
- Camazepam
- Carburazepam
- Chlordiazepoxide
- Cinazepam
- Cinolazepam
- Clonazepam
- Cloniprazepam
- Clorazepate
- Cyprazepam
- Delorazepam
- Demoxepam
- Desmethylflunitrazepam
- Devazepide*
- Diazepam
- Diclazepam
- Difludiazepam
- Doxefazepam
- Elfazepam
- Ethyl carfluzepate
- Ethyl dirazepate
- Ethyl loflazepate
- Flubromazepam
- Fletazepam
- Fludiazepam
- Flunitrazepam
- Flurazepam
- Flutemazepam
- Flutoprazepam
- Fosazepam
- Gidazepam
- Halazepam
- Iclazepam
- Irazepine*
- Kenazepine
- Ketazolam
- Lorazepam
- Lormetazepam
- Lufuradom*
- Meclonazepam
- Medazepam
- Menitrazepam
- Metaclazepam
- Motrazepam
- N-Desalkylflurazepam
- Nifoxipam
- Nimetazepam
- Nitemazepam
- Nitrazepam
- Nitrazepate
- Nordazepam
- Nortetrazepam
- Oxazepam
- Phenazepam
- Pinazepam
- Pivoxazepam
- Prazepam
- Proflazepam
- Quazepam
- QH-II-66
- Reclazepam
- RO4491533*
- Ro05-4082
- Ro5-4864*
- Ro07-5220
- Ro07-9749
- Ro20-8065
- Ro20-8552
- SH-I-048A
- Sulazepam
- Temazepam
- Tetrazepam
- Tifluadom*
- Timelotem*
- Tolufazepam
- Triflunordazepam
- Tuclazepam
- Uldazepam
* atypical activity profile (not GABAA receptor ligands)